Singapore markets closed
Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
61,015.43 -403.49 (-0.66%) CMC Crypto 200
1,268.75 -15.08 (-1.17%)
ITCI Jul 2024 65.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:50PM EDT
| Previous close | 11.4300 |
| Open | 4.6000 |
| Bid | 4.0000 |
| Ask | 6.7000 |
| Strike | 65.00 |
| Expiry date | 2024-07-19 |
| Day's range | 4.4000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.